Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5-15% and PGA ≥ 3: Post-Hoc Analysis From Three Randomized Controlled Trials

Lars Iversen, Merle Kurvits, Anja Marieke Snel-Prentø, Alan Menter, Lars Iversen, Merle Kurvits, Anja Marieke Snel-Prentø, Alan Menter

Abstract

Introduction: Psoriasis is a chronic, inflammatory disease, which ranges in severity from mild to severe. Although topical therapies are frequently used to treat mild disease, they are not routinely used to treat patients with moderate-to-severe disease who have a larger proportion of their body surface area (BSA) affected (≥ 5% BSA). Based on well-controlled trials in adults with mild-to-severe disease, fixed-dose combination calcipotriol 50 μg/g + betamethasone dipropionate 0.5 mg/g (Cal/BD) cutaneous foam has been approved (Enstilar®, LEO Pharma) in the USA and EU for the treatment of psoriasis vulgaris for up to 4 weeks in adults. In this post-hoc subgroup analysis, we used pooled data from phase II/III trials to investigate the efficacy and safety of Cal/BD cutaneous foam in patients with moderate-to-severe psoriasis.

Methods: Patients included in this analysis had psoriasis affecting 5-15% BSA and a physician's global assessment (PGA) ≥ 3. Endpoints included: treatment success by PGA (rating: clear/almost clear), patient's global assessment (PaGA) at week 4 (rating: clear/very mild) and safety.

Results: A total of 340 patients in the three randomized trials met the BSA/PGA inclusion criteria, of whom 254 were treated with Cal/BD foam and 86 with vehicle foam. Treatment success by PGA and PaGA at week 4 was achieved in 143 (58.1%) and 138 (56.1%) patients receiving Cal/BD foam, respectively, versus three (3.6%) and 14 (16.7%) patients receiving vehicle foam. Sixty-six adverse events (AEs) occurred in 47 (18.5%) patients receiving Cal/BD foam and 11 AEs occurred in 11 (12.8%) patients receiving vehicle foam. Three severe AEs and 15 non-serious treatment-related AEs occurred in patients receiving Cal/BD foam.

Conclusion: The results from three clinical trials analyzed together show that topical Cal/BD foam is well tolerated and efficacious for treating patients with moderate-to-severe disease. Data support Cal/BD foam as a potential topical therapy for moderate-to-severe psoriasis.

Trial registrations: ClinicalTrials.gov registration numbers: NCT01866163, NCT02132936, NCT01536886.

Keywords: BSA ≥ 5%; Betamethasone dipropionate; Calcipotriol; Enstilar; Foam; Moderate-to-severe; PGA ≥ 3; Post-hoc; Psoriasis; Topical application.

Figures

Fig. 1
Fig. 1
Treatment success at week 4 by physician’s global assessment (PGA) and patient’s global assessment (PaGA) in the group treated with the fixed-dose combination calcipotriol/betamethasone dipropionate cutaneous foam (Cal/BD foam) and the group treated with vehicle (foam vehicle)
Fig. 2
Fig. 2
Mean itch score in the Cal/BD foam and foam vehicle groups
Fig. 3
Fig. 3
Mean modified Psoriasis Area and Severity Index (mPASI) in the Cal/BD foam and foam vehicle groups

References

    1. Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 3. Guidelines of care for the management and treatment of psoriasis with topical therapies. J Am Acad Dermatol. 2009;60:643–659. doi: 10.1016/j.jaad.2008.12.032.
    1. Elmets CA, Leonardi CL, Davis DMR, et al. Joint AAD–NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol. 2019;80:1073–1113. doi: 10.1016/j.jaad.2018.11.058.
    1. Balato N, Napolitano M, Ayala F, et al. Nonalcoholic fatty liver disease, spleen and psoriasis: New aspects of low-grade chronic inflammation. World J Gastroenterol. 2015;21:6892–7.
    1. Raychaudhuri SK, Maverakis E, Raychaudhuri SP. Diagnosis and classification of psoriasis. Autoimmunity Rev. 2014;13:490–495. doi: 10.1016/j.autrev.2014.01.008.
    1. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80:1029–72. doi: 10.1016/j.jaad.2018.11.057.
    1. Lind M, Nielsen KT, Schefe LH, et al. Supersaturation of calcipotriene and betamethasone dipropionate in a novel aerosol foam formulation for topical treatment of psoriasis provides enhanced bioavailability of the active ingredients. Dermatol Ther. 2016;6:413–25. doi: 10.1007/s13555-016-0125-6.
    1. Electronic medicines compendium (EMC). Enstilar cutaneous foam—summary of product characteristics. 2018. . Accessed 6 Dec 2018.
    1. US Food and Drug Administration. Enstilar—prescribing information. 2018. . Accessed 6 Dec 2018.
    1. Leonardi C, Bagel J, Yamauchi P, et al. Efficacy and safety of calcipotriene plus betamethasone dipropionate aerosol foam in patients with psoriasis vulgaris–a randomized phase III study (PSO-FAST) J Drugs Dermatol. 2015;14:1468–1477.
    1. Paul C, Stein Gold L, Cambazard F, et al. Calcipotriol plus betamethasone dipropionate aerosol foam provides superior efficacy vs. gel in patients with psoriasis vulgaris: randomized, controlled PSO-ABLE study. J Eur Acad Dermatol Venereol. 2017;31:119–126. doi: 10.1111/jdv.13859.
    1. Koo J, Tyring S, Werschler WP, et al. Superior efficacy of calcipotriene and betamethasone dipropionate aerosol foam versus ointment in patients with psoriasis vulgaris—a randomized phase II study. J Dermatolog Treat. 2016;27:120–127. doi: 10.3109/09546634.2015.1083935.
    1. Pinter A, Thormann H, Angeletti F, Jalili A. Calcipotriol/betamethasone dipropionate aerosol foam for the treatment of psoriasis vulgaris: case series and review of the literature. Clin Cosmet Investig Dermatol. 2018;11:451–459. doi: 10.2147/CCID.S180698.
    1. Gerdes S, Krakor M, Anger T, Hutt HJ, Korber A. Prospective, observational, non-interventional, multicentre study on the efficacy and tolerability of a new calcipotriol/betamethasone aerosol foam (Enstilar®) in patients with plaque psoriasis under daily practice conditions. Dermatology. 2017;233:425–434. doi: 10.1159/000486700.
    1. Gallo L, Megna M, Cirillo T, et al. Psoriasis and skin pain: real-life effectiveness of calcipotriol plus betamethasone dipropionate in aerosol foam formulation. J Eur Acad Dermatol Venereol. 2019;33:1312–5. doi: 10.1111/jdv.15488.
    1. Torsekar R, Gautam MM. Topical therapies in psoriasis. Indian Dermatol Online J. 2017;8:235–245. doi: 10.4103/2229-5178.209622.
    1. Hjuler KF, Iversen L, Rasmussen MK, Kofoed K, Skov L, Zachariae C. Localization of treatment-resistant areas in patients with psoriasis on biologics. Br J Dermatol. 2019;181:332–337. doi: 10.1111/bjd.17689.
    1. Taraska V, Tuppal R, Olesen M, Bang Pedersen C, Papp K. A novel aerosol foam formulation of calcipotriol and betamethasone has no impact on HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris. J Cutan Med Surg. 2016;20:44–51. doi: 10.1177/1203475415597094.
    1. Bewley A, Page B. Maximizing patient adherence for optimal outcomes in psoriasis. J Eur Acad Dermatol Venereol. 2011;25(Suppl 4):9–14. doi: 10.1111/j.1468-3083.2011.04060.x.
    1. Zaghloul SS, Goodfield MJ. Objective assessment of compliance with psoriasis treatment. Arch Dermatol. 2004;140:408–414. doi: 10.1001/archderm.140.4.408.
    1. Seston EM, Ashcroft DM, Griffiths CE. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis. Arch Dermatol. 2007;143:1175–1179. doi: 10.1001/archderm.143.9.1175.
    1. Pink AE, Jalili A, Berg P, et al. Rapid onset of action of calcipotriol/betamethasone dipropionate cutaneous foam in psoriasis, even in patients with more severe disease. J Eur Acad Dermatol Venereol. 2019;33:1116–1123. doi: 10.1111/jdv.15398.
    1. Devaux S, Castela A, Archier E, et al. Adherence to topical treatment in psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol. 2012;26(Suppl 3):61–67. doi: 10.1111/j.1468-3083.2012.04525.x.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel